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Background: We present a large European population-
based study of thyroid function, performed in a popu-
lation with longstanding borderline sufficient iodine
intake.
Methods: The Nijmegen Biomedical Study is a popula-
tion-based survey conducted in the eastern part of The
Netherlands. Randomly selected inhabitants received a
postal questionnaire on lifestyle and medical history,
which was filled out by 9371 individuals (41.7%). We
measured serum thyroid-stimulating hormone (TSH),
free thyroxine (FT4), and anti-thyroperoxidase antibod-
ies (TPOAbs) in 6434 responders. A reference popula-
tion of 5167 individuals was selected by excluding those
at risk for thyroid disease.
Results: Overt thyrotoxicosis was found in 0.4% of the
total population and subclinical thyrotoxicosis in 0.8%.
Overt hypothyroidism was found in 0.4% and subclin-
ical hypothyroidism in 4.0%. In individuals older than
60 years, mean FT4 concentrations increased with age.
Mean TSH decreased with age, from 1.46 mIU/L at 18–24
years to 1.07 mIU/L after 85 years. The mean TSH in the
total population did not differ from the mean TSH in
the reference population; the exclusion of those at risk
for thyroid disease, however, lowered the upper limit of
the TSH reference interval considerably. In the total
population, 8.6% of males and 18.5% of females had
positive TPOAbs. The presence of TPOAbs was associ-
ated with abnormally high and low TSH concentrations.
Conclusion: In inhabitants of the eastern part of The
Netherlands, serum TSH gradually decreases with age,
whereas after age 60, serum FT4 increases, possibly
because of the development of thyroid autonomy after
longstanding borderline sufficient iodine intake.
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Thyroid dysfunction is common (1–4). In the Third Na-
tional Health and Nutrition Examination Survey
(NHANES III),5 a recent large population-wide survey in
the United States, hypothyroidism was found in 4.6%
(0.3% overt and 4.3% subclinical) and hyperthyroidism in
1.3% (0.5% overt and 0.7% subclinical) of the total popu-
lation (2 ). Interpretation of data on the prevalence of
thyroid disease in a certain area must take into account
the influence on these data of the iodine intake in that
region. A high iodine intake is associated with lower
prevalence of goiter and higher prevalence of hypothy-
roidism, whereas a low iodine intake is associated with a
higher prevalence of hyperthyroidism (5 ). Sex and age are
also important, e.g., hypothyroidism is far more common
among elderly women than among other groups, partic-
ularly in the presence of thyroid autoantibodies (1–3, 6).
The NHANES III study found a median serum thyroid-
stimulating hormone (TSH) concentration in the total
population of 1.49 mIU/L with 2.5th and 97.5th percen-
tiles of 0.33 and 5.8 mIU/L, respectively (2 ). However, in
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a reference population (excluding those who self-reported
thyroid disease or pregnancy, use of thyroid medication,
estrogens, androgens, or lithium; those with detectable
thyroid antibodies; and/or those with laboratory evi-
dence of hyper- or hypothyroidism), the median serum
TSH concentration was 1.39 mIU/L with 2.5th and 97.5th
percentiles of 0.45 and 4.12 mIU/L, respectively. The
difference in TSH values between these 2 populations,
particularly the 97.5th percentiles, has initiated a discus-
sion on whether the TSH reference interval should be
based on the total population or on such a reference
population (7 ).
To date, there has not been a European population-
based study of this size in which participants have had
their serum TSH (using a third-generation assay), free
thyroxine (FT4), and anti-thyroperoxidase antibodies
(TPOAbs) determined with a sensitive assay. We collected
data on a large population from the city of Nijmegen, in
the eastern part of The Netherlands close to the German
border, where inhabitants have borderline sufficient io-
dine intake (8, 9). We measured the prevalence of thyroid
dysfunction and TPOAbs in inhabitants of Nijmegen and
investigated whether thyroid function in this area is
influenced by age, as was seen in other large studies
(1, 10), and whether the TSH reference interval, as in




The Nijmegen Biomedical Study is a population-based
survey conducted by the Department of Epidemiology
and Biostatistics and the Department of Clinical Chemis-
try of the Radboud University Nijmegen Medical Centre.
Approval to conduct the study was obtained from the
Institutional Review Board. Nijmegen is a town in the
eastern part of The Netherlands with 156 000 inhabitants,
87% of Caucasian descent. Age- and sex-stratified ran-
domly selected adult inhabitants of Nijmegen (n 22 452)
received an invitation to fill out a postal questionnaire on
lifestyle and medical history. Three questions were used
to collect data on thyroid disease and thyroid medication:
Has thyroid disease ever been diagnosed in you by a
doctor, and if yes, at what age? What kind of operations
did you have? Which medication did you use for at least
6 months or are you currently using?
A total of 9371 (41.7%) recipients responded to the
questionnaire, and 6455 (68.9%) of the responders each
donated 8.5 mL of blood. Serum TSH, FT4, and TPOAbs
were measured in all of these samples. For 21 samples, the
blood volume obtained was insufficient to determine
TSH, FT4, and/or TPOAbs. No physical examination was
done. We analyzed results for 6434 participants, 46.3%
male and 53.7% female. The highest number of partici-
pants was in the 60–69 years age group, and the lowest
number in the 85 years and older group (see Table 1 in the
Data Supplement that accompanies the online version of
this article at http://www.clinchem.org/content/vol52/
issue1/). Almost all participants (96.0%) were of Cauca-
sian descent. Of the total population (n  6434), 5.3% (261
females and 79 males) reported thyroid disease (n  328),
and/or thyroid surgery (n  41), and/or the use of
thyroid medication [l-thyroxine (n  102), thyrostatic
drugs (n  18), or both (n  6)]. The remaining 6094
participants were defined as the disease-free population.
A reference population of 5167 participants (80.3% of
the total population) was selected, excluding those who
reported thyroid disease, and/or thyroid surgery, and/or
thyroid medication use (n  340); pregnant women (n 
24); those who did not report thyroid disease but who
evinced overt thyrotoxicosis (n 8) or overt hypothyroid-
ism (n  23); those on lithium (n  23), amiodarone (n 
11), kelp (n  3), oral glucocorticoids (n  114), or
dopamine agonists (n  12); and those with positive
TPOAbs with or without other exclusionary characteris-
tics (n  897).
laboratory methods
We measured serum TSH by an immunoluminometric
assay on a random-access analyzer (Architect; Abbott
Diagnostics Division). The between-run SD of a control
sample with a very low TSH concentration (0.0348
mIU/L) was 0.0013 mIU/L. This value is assumed to be
representative for lower concentrations as well. Thus, at a
concentration of 0.007 mIU/L the between-assay CV will
be 20%. This value of 0.007 mIU/L was considered as
the functional detection limit. At higher concentrations,
between-run CVs were as follows: 3.3% at 0.250 mIU/L;
3.6% at 1.72 mIU/L; and 3.0% at 9.86 mIU/L. The refer-
ence interval used in our laboratory is 0.4–4.0 mIU/L.
We measured serum FT4 with a luminescence enzyme
immunoassay on a random-access assay system (Vitros
ECI; Ortho Clinical Diagnostics). This assay uses a labeled
anti-T4 antibody in a medium that is essentially free of
other extraneous T4-binding proteins. Serum samples
may be diluted up to 8-fold without significant effects on
measurement results. Between-run CVs were as follows:
3.8% at 10.1 pmol/L; 4.5% at 15.8 pmol/L; and 4.6% at
28.7 pmol/L. Our laboratory reference interval is 8.0–22.0
pmol/L.
TPOAbs were measured with a fluorescence immu-
noenzymometric assay for the quantitative measurement
of the IgG class of anti-thyroperoxidase antibodies (Ax-
SYM Anti-TPO; Abbott Diagnostics Division). The refer-
ence interval was defined as 12 kIU/L (data provided
by manufacturer). The mean value for a negative control
sample was 4.1 kIU/L (between-run CV of 13%); a posi-
tive control sample averaged 64.2 kIU/L (between-run
CV, 7.3%). The functional detection limit was estimated in
the same way as for TSH; the CV of 13% at 4.1 kIU/L
implies a 20% CV at 2.6 kIU/L, assuming that the SD does
not decrease further with concentration.
The precision data cited above all pertain to the period
in which the assays for this study were performed (10
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weeks). Blood was drawn September 2002 through De-
cember 2003, between 0800 in the morning and 2000 in the
evening.
data analysis
Thyrotoxicosis was classified as overt if TSH was 0.1
mIU/L and FT4 22 pmol/L and as subclinical if TSH
was 0.1 mIU/L and FT4 22 pmol/L. Hypothyroidism
was classified as overt if TSH was 4.0 mIU/L and FT4
8.0 pmol/L and as subclinical if TSH was 4.0 mIU/L
and FT4 8.0 pmol/L. A TSH concentration of 0.1–0.4
mIU/L was considered mildly suppressed. We analyzed
all data with the SPSS 12.0 statistical software package
(SPSS Inc.). For TSH, we calculated the means, SE, and
SD from log-transformed values, and for FT4 we used
arithmetic means. To generate possible reference values
for TSH, we calculated the 95% probability intervals with
the mean (1.96)  SD from log-transformed values in 3
different populations (total, disease-free, and reference
population, as defined above) (7 ). We considered the 95%
probability interval of the reference population the refer-
ence interval for TSH values. To study the characteristics
of persons with high or low TSH values and/or positive
TPOAb values, we calculated prevalence and prevalence
differences.
Results
prevalence of thyroid dysfunction
Thyroid disease, thyroid surgery, and/or thyroid medi-
cation use were reported by 261 females and 79 males,
5.3% of the total population. Of those on l-thyroxine (108
persons; 1.7%), 11.1% were classified having overt thyro-
toxicosis and 9.3% as having subclinical thyrotoxicosis,
13.9% showed a mildly suppressed TSH, and 12.0% were
classified as subclinical hypothyroid. Only 53.7% showed
a TSH in the reference interval while on l-thyroxine.
In the total population, the prevalence of overt thyro-
toxicosis was 0.4% (20 females and 7 males; age range,
24–85 years; Table 1). The majority (19 of 27) of those with
overt thyrotoxicosis reported thyroid disease, thyroid
surgery, and/or use of thyroid medication: 44.4% used
l-thyroxine and 7.4% thyrostatic drugs. Of the 21 persons
with FT422 pmol/L and TSH0.1 mIU/L, 5 were using
l-thyroxine and 7 amiodarone. There were 52 persons
(0.8% of the total population; 12 males and 40 females)
with subclinical thyrotoxicosis. One woman was preg-
nant; she did not report thyroid disease. No persons with
subclinical thyrotoxicosis reported use of TSH-influencing
medications such as oral glucocorticoids or dopamine
agonists. Several participants reported use of thyroid
medication: 9 used l-thyroxine, 2 used thyrostatic drugs,
and 1 used both. Another 202 individuals (3.1% of the
total population) showed mildly suppressed TSH com-
bined with FT4 concentrations within the reference inter-
val.
Overt hypothyroidism was found in 26 individuals
(0.4% of the total population; 5 males and 21 females; age
range, 32–80 years). Only 3 of 26 (11.5%) of those with
hypothyroidism reported a history of thyroid disease. Of
these individuals, none was using thyroid medications,
and TPOAbs were detected in 88.5% (Table 1). Subclinical
hypothyroidism was found in 4.0% of the total popula-
tion, more frequently in females than males; of those with
subclinical hypothyroidism, 13.5% reported thyroid dis-
ease, thyroid surgery, and/or use of thyroid medications
(12 used l-thyroxine and 1 used thyrostatic drugs), and
61.4% were found to have positive TPOAbs.
ft4
The mean FT4 for all participants was 13.56 pmol/L
[95% confidence interval (95% CI), 13.50–13.62 pmol/L].
There was no difference in mean FT4 between the total,
disease-free, and reference populations (see Fig. 1 in
the online Data Supplement). In male and female par-
ticipants older than 60 years, mean FT4 increased with
age (Fig. 1). The lowest mean FT4 [13.0 pmol/L (95% CI,
12.8–13.2 pmol/L)] was found in participants 30–34 years
of age. In participants older than 85 years, mean FT4 was











Overt thyrotoxicosis 27 (0.4%) 7 (0.2%) 20 (0.6%) 19 (70.4%) 11 (40.7%)
Subclinical thyrotoxicosis 52 (0.8%) 12 (0.4%) 40 (1.2%) 22 (42.3%) 16 (30.8%)
Mildly suppressed TSH and
normal FT4
202 (3.1%) 85 (2.9%) 117 (3.4%) 28 (13.9%) 30 (14.9%)
Euthyroid 5838 (90.7%) 2762 (92.8%) 3076 (89.0%) 224 (3.8%) 654 (11.2%)
Subclinical hypothyroidism 259 (4.0%) 90 (3.0%) 169 (4.9%) 35 (13.5%) 159 (61.4%)
Overt hypothyroidism 26 (0.4%) 5 (0.2%) 21 (0.6%) 3 (11.5%) 23 (88.5%)
a Results of TSH, FT4, and TPOAb measurements were available for 6434 individuals. Thyrotoxicosis was classified as overt if TSH was 0.1 mIU/L and FT4 22
pmol/L and as subclinical if TSH was 0.1 mIU/L and FT4 22 pmol/L. Hypothyroidism was classified as overt if TSH was 4.0 mIU/L and FT4 8.0 pmol/L and
as subclinical if TSH was4.0 mIU/L and FT48.0 pmol/L. A TSH concentration between 0.1 and 0.4 mIU/L was considered mildly suppressed. Not included in Table
2 are persons with a TSH concentration between 0.4 and 4.0 mIU/L and a FT4 concentration 8 pmol/L (n  9), and persons with a TSH between 0.1 and 10.0 mIU/L
and FT4 22 pmol/L (n  21).
b Thyroid pathology means reporting thyroid disease, thyroid surgery, and/or use of L-thyroxine and/or thyrostatic drugs. This group consisted of 340 individuals, of
whom 9 are not included in the table because they belong to the group of 30 persons mentioned above who were not included in Table 2.
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15.2 pmol/L (95% CI, 14.7–15.6). The increase in FT4 with
age was seen in the total, disease-free, and reference
populations (Fig. 1 in the online Data Supplement). The
highest FT4 value (52.1 pmol/L) was found in a 55-year-
old woman with fully suppressed TSH and the lowest
(2.1 pmol/L) in a 38-year-old woman with a TSH of
94.42 mIU/L. Neither reported thyroid disease or use of
thyroid medication.
The mean FT4 concentration, after correction for age
and sex, was 0.50 pmol/L (95% CI, 0.32–0.68 pmol/L) and
was lower in those with positive TPOAbs than in those
with negative TPOAbs.
tsh
TSH decreased gradually with age in both males and
females (Fig. 2). The (geometric) mean TSH was
1.46 mIU/L (95% CI, 1.36–1.57 mIU/L) in those 18–24
years of age and 1.07 mIU/L (95% CI, 0.92–1.24 mIU/L) in
those over 85 years of age. The mean TSH in the total
population did not differ from the mean TSH in the
reference population: 1.29 (95% CI, 1.26–1.32) mIU/L vs
1.26 (1.24–1.29) mIU/L. In the overall, the disease-free,
and the reference populations, the mean TSH concentra-
tions were lower in the older age group (Table 2).
We used the log-transformed values of TSH to calcu-
late the 95% probability intervals for the different popu-
lations to obtain possible reference values (7 ) (Table 2).
The lower limits of the 95% probability intervals of the 3
populations were only marginally different; however, the
upper limit of the total population was considerably
higher than the upper limit of the reference population.
The largest difference was seen in the 55–59 years age
group, in which the reference population had an upper
limit of 3.82 mIU/L, whereas the total population had an
upper limit of 8.17 mIU/L.
TPOAbs
TPOAbs were found more frequently in females than in
males (Table 3). Women 75–79 years of age had the
highest percentage, 25.5%, compared with 8.5% in women
18–24 years of age. Among men, the highest percentage
was seen men 70–74 years of age (14.3%), whereas no
TPOAbs were found in men 18–24 years of age.
In the group that reported thyroid disease, thyroid
surgery, and/or use of thyroid medications, 31.6% of
males and 42.9% of females had TPOAbs. In the total
population, these proportions were 8.6% for males and
18.5% for females. TSH values outside the reference
interval were associated with a higher prevalence of
positive TPOAbs (Fig. 3). Among all participants with a
TSH concentration between 0.4 and 4.0 mIU/L, 11.0% had
positive TPOAb results, and among all participants with a
TSH concentration 0.1 mIU/L, 35.1% had positive
TPOAb results. The highest positive TPOAb rate (81.3%)
was found among individuals with a TSH 10 mIU/L.
Fig. 1. Mean serum FT4 in different age groups (by sex) in the total
population.
The total population consists of 6434 adults. The error bars represent 95% CIs
of arithmetic means, calculated using the SE. f, males; , females.
Fig. 2. Geometric mean serum TSH in different age groups (by sex) in
the total population.
The total population consists of 6434 adults. The error bars represent 95% CIs
of means, calculated using the SE calculated from log-transformed values.
f, males; , females.
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Discussion
In a large population inhabiting an area with border-
line sufficient iodine intake, thyrotoxicosis was found
in 1.2% (overt in 0.4%, subclinical in 0.8%) and hypo-
thyroidism in 4.4% (overt in 0.4%, subclinical in 4.0%)
of adults. TPOAb results were positive in 8.6% of males
and in 18.5% of females, and the presence of TPOAbs was
associated with abnormal thyroid function. In partici-
pants older than 60 years, mean FT4 concentrations in-
Fig. 3. Percentages of males (f) and females (u) in the total
population with positive TPOAbs for different serum TSH ranges.
Table 2. Serum TSH (geometric mean and upper and lower limits of 95% probability interval) in the different age groups for











Lower limit Upper limit Lower limit Upper limit Lower limit Upper limit
18–24 1.46 0.40 5.39 1.49 0.53 4.23 1.47 0.54 4.03
25–29 1.48 0.42 5.15 1.50 0.50 4.49 1.42 0.56 3.60
30–34 1.44 0.35 5.83 1.46 0.39 5.50 1.44 0.55 3.78
35–39 1.42 0.34 5.89 1.43 0.37 5.58 1.35 0.50 3.61
40–44 1.37 0.29 6.48 1.40 0.35 5.63 1.35 0.47 3.82
45–49 1.31 0.21 8.06 1.38 0.39 4.80 1.31 0.46 3.70
50–54 1.28 0.26 6.30 1.31 0.32 5.38 1.26 0.36 4.45
55–59 1.35 0.22 8.17 1.39 0.29 6.62 1.34 0.47 3.82
60–64 1.31 0.21 8.31 1.37 0.29 6.50 1.28 0.37 4.47
65–69 1.20 0.17 8.32 1.23 0.21 7.11 1.16 0.25 5.53
70–74 1.26 0.18 8.64 1.27 0.21 7.86 1.14 0.22 5.82
75–79 1.12 0.16 7.68 1.16 0.21 6.34 1.10 0.24 4.97
80–84 1.09 0.16 7.62 1.15 0.22 6.09 1.07 0.22 5.26
85 1.07 0.13 8.99 1.08 0.14 8.33 1.07 0.13 8.66
All 1.29 0.22 7.43 1.33 0.29 6.15 1.26 0.34 4.66
a The total population consisted of 6434 adults. The disease-free population consisted of 6094 adults: the total population minus those self-reporting thyroid
disease, thyroid surgery, and/or taking thyroid medication (n  340). The reference population consisted of 5156 adults, the disease-free population minus the
following: pregnant women; those with overt thyrotoxicosis or overt hypothyroidism; those using lithium, amiodarone, kelp, oral glucocorticoids, and/or dopamine
agonists; and/or those with positive TPOAbs.
b The 95% probability intervals for TSH were calculated using the mean  1.96(SD) from log-transformed values.
Table 3. Percentage of persons with positive TPOAbs in the





Total population Disease-free population
Males Females Males Females
18–24 0.0 8.5 0 8.6
25–29 5.2 14.5 5.2 14.7
30–34 4.4 15.4 4.4 14.0
35–39 7.2 16.0 7.2 14.6
40–44 7.1 17.5 6.1 15.9
45–49 6.5 19.2 6.2 16.2
50–54 7.9 18.1 7.5 16.5
55–59 8.2 20.0 7.3 18.8
60–64 9.4 22.3 9.2 18.9
65–69 10.4 22.0 9.3 18.9
70–74 14.3 21.0 13.9 17.3
75–79 9.8 25.5 9.4 24.6
80–84 8.7 17.5 6.5 17.5
85 10.0 16.1 9.2 12.0
Overall 8.6 18.5 8.0 16.5
a The total population consisted of 6434 adults. The disease-free population
consisted of 6094 adults: the total population minus those self-reporting thyroid
disease, thyroid surgery, and/or taking thyroid medication (n  340).
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creased with age, whereas in all participants, TSH con-
centrations decreased gradually with age throughout life.
The lower limits of the 95% probability intervals of the
TSH concentrations of the total and the reference popu-
lations were only marginally different, but the upper limit
of the 95% probability interval of the TSH concentrations
in the total population was considerably higher than the
upper limit in the reference population.
Our study can be compared with several other popu-
lation-based studies. The Whickham survey, performed in
the northeastern part of England at a time when no
sensitive TSH assays were available, found thyrotoxicosis
in 1.6%, overt hypothyroidism in 1.1%, and a TSH con-
centration 6 mIU/L in 5.0% of participants (3 ). The
prevalence of overt hypothyroidism in our study is lower
than that in the Whickham survey but in line with the
findings of NHANES III (2 ). We found the same preva-
lence of subclinical hypothyroidism as in Whickham, an
iodine-replete area. A large study performed in Colorado
with a TSH cutoff concentration of 5.1 mIU/L found twice
as much subclinical hypothyroidism (9.0%) (1 ). A Danish
survey in an area with borderline iodine deficiency found
thyrotoxicosis in 2.0% and hypothyroidism in 1.4% of the
participants, with subclinical hypothyroidism in only
0.6% of participants (11 ). German researchers recently
concluded that reference intervals of thyroid function
tests in a formerly iodine-deficient region are distinct
from the reference intervals that were established in areas
with iodine sufficiency (12 ).
Thyroid abnormalities in populations with low iodine
intake and in those with high iodine intake develop in
opposite directions: more goiter and thyroid hyperfunc-
tion are seen when iodine intake is relatively low, whereas
more hypothyroidism is seen when iodine intake is rela-
tively high. This trend was demonstrated very elegantly
in a study by Laurberg et al. (5 ), which compared elderly
persons in Iceland (an area with a high iodine intake) with
elderly persons in Jutland (an area with a low iodine
intake). In Iceland, hypothyroidism was common, and
none of the participants had a TSH concentration
0.4 mIU/L, whereas in Jutland, hyperthyroidism was
common and hypothyroidism rare. The pattern of thyroid
dysfunction seen in our study is compatible with a
(marginally) sufficient iodine intake in our area.
The principal difference in results between our study
and the NHANES III survey is the decrease of TSH with
age in our study, whereas in NHANES III an increase in
TSH with age was reported. A possible explanation for
this discrepancy is the difference in iodine intake. In the
United States, iodine intake has been relatively high in the
past, as demonstrated by the NHANES I survey in the
early 1970s, which found urine iodine concentrations
500 g/L in 27.8% of the population (10 ). According to
the International Council for the Control of Iodine Defi-
ciency Disorders (ICCIDD), The Netherlands currently is
an iodine-sufficient area. Indeed, a study in 2001 found
that goiter was rare among Dutch schoolchildren (13 ).
However, in the past goiter was prevalent in The Neth-
erlands, and for that reason iodization of bread salt was
made mandatory in 1968. Nevertheless, in 1985/1986, the
prevalence of goiter was 38%–45% among girls and
20%–31% among boys in the eastern parts of The Neth-
erlands (14 ). Moreover, several studies conducted in
1981–1993 showed that urinary iodine excretion was
100 g/24 h in 13%–50% of individuals in The Nether-
lands (8, 9).
It is well known that in patients with a goiter attribut-
able to long-standing iodine deficiency, autonomously
functioning thyroid tissue, characterized by the ability to
function without TSH stimulation, can develop within
the goiter and lead to subclinical and, later, overt thyro-
toxicosis (15 ). Iodine deficiency induces thyroid hyper-
plasia in children and nodular transformation and ulti-
mately autonomous function of the thyroid later in life
(16 ), as illustrated by a population-based study in a
previously iodine-deficient area of Germany. This study
found that the prevalence of thyroid nodules increased
with every decade of life and that persons with nodules
had a lower median TSH concentration (17 ). The lower
TSH concentrations and higher FT4 concentrations among
the elderly in our study suggest more autonomous thy-
roid function in this group, possibly caused by the rela-
tively low iodine intake in the past (18 ). Apparently, the
iodine intake in Nijmegen has not been so insufficient as
to lead to rates of hyperthyroidism as high as those in
truly iodine-insufficient areas such as Jutland. Neither has
the iodine intake in the United States been high enough to
increase the rates of hypothyroidism to those of areas of
clear iodine excess, such as Iceland (5 ).
TPOAbs are considered to be a sensitive marker for
autoimmune thyroid disease (19 ). In NHANES III, posi-
tive TPOAbs were detected in 8.7% of males and 17.0% of
females. In our survey, we found TPOAbs in 8.6% of
males and 18.5% of females in the total population. A
small difference between NHANES III and our survey is
that NHANES III found a progressive increase with age in
the percentage of people with positive TPOAb results,
whereas we observed a maximum value in the 70–79
years age group. A possible explanation for the slightly
lower percentage of positive TPOAbs found among those
older than 80 years compared with those in their 70s is the
selection of healthy seniors in our survey (20 ). Partici-
pants were not institutionalized and had to be able to fill
out an extensive questionnaire. In this way, we may have
excluded individuals at higher risk for thyroid autoim-
munity. As expected, TPOAbs were found more often in
the group that reported thyroid disease, thyroid surgery,
and/or use of thyroid medication. As in a study per-
formed in Norway, TPOAbs were associated with abnor-
mally low and high TSH concentrations (21 ).
Earlier studies found that the prevalence of undiag-
nosed thyroid disorders is high (1, 2, 11, 21). There is an
ongoing debate as to whether screening for thyroid dys-
function is useful in the general population (22–24). In
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6434 individuals over 18 years of age, we found 31
persons (0.5%) with unknown overt thyroid hyper- or
hypofunction. Of the 27 individuals found to have hyper-
thyroidism, 8 were unaware of their thyroid disease.
Hypothyroidism seemed to remain unnoticed more often:
23 of the 26 individuals with overt hypothyroidism did
not report thyroid disease.
An even more controversial issue is whether screen-
ing for subclinical thyroid dysfunction is indicated
(22, 25, 26). Surks et al. (25 ) concluded recently that there
is insufficient evidence to support population-based
screening for this condition because there are no con-
vincing data from controlled trials that early treatment
reduces morbidity in patients detected by screening. We
found 259 individuals with subclinical hypothyroidism,
of whom only 35 (13.5%) reported thyroid disease.
TPOAbs were found in 61.4% of those 259 individuals, an
important finding because the presence of TPOAbs in
subclinical hypothyroidism is known to be associated
with a higher risk of developing overt hypothyroidism
later in life (27 ). Subclinical thyrotoxicosis is associated
with an increased risk of atrial fibrillation (28 ) and
osteoporosis (29, 30). We found 52 persons with subclin-
ical thyrotoxicosis, of whom 22 (42.3%) were known to
have thyroid disease and 10 (19.2%) reported l-thyroxine
use. Our data show that more attention should be given to
proper dosing in l-thyroxine therapy because 46.3% of
those on l-thyroxine in our study had a serum TSH
concentration outside the reference interval. NHANES III
found that only 67% of those with thyroid disease had
thyroid function tests in the euthyroid range (2 ).
It has been proposed that reference intervals for thy-
roid function tests should be based on the 95% prob-
ability intervals obtained in a well-selected group of
healthy people (7 ). NHANES III, a survey designed to
give national normative estimates of the health and nu-
tritional status of the US population (17 353 participants
older than 12 years), found in the total population a
median serum TSH of 1.49 mIU/L with 2.5th and 97.5th
percentiles of 0.33 and 5.8 mIU/L, respectively (2 ). How-
ever, in a reference population (excluding individuals
with self-reported thyroid disease, goiter, taking thyroid
medication, pregnancy, estrogen or androgen use, lith-
ium, detectable thyroglobulin autoantibodies, TPOAbs, or
laboratory evidence of hyper- or hypothyroidism), me-
dian TSH was 1.39 mIU/L with 2.5th and 97.5th percen-
tiles of 0.45 and 4.12 mIU/L. In our survey, the geometric
mean TSH in the total population was 1.29 mIU/L, with
the upper and lower limits of the 95% probability interval
being 0.22 and 7.43 mIU/L, respectively. In selecting a
reference population, we used criteria comparable to
those used in NHANES III and found that the geometric
mean TSH in the reference population was 1.26 mIU/L
with the upper and lower limits of the 95% probability
interval being 0.34 and 4.66 mIU/L, respectively. In our
study, therefore, as in NHANES III, the lower limit in the
2 populations was about the same, but the upper limit
was considerably lower in the reference population than
in the total population.
It is interesting to note that the skewed distribution of
TSH values persisted after exclusion of those individuals
with positive TPOAbs. The use of TPOAb screening,
however, does not lead to the detection of all individuals
with mild thyroid failure attributable to autoimmunity, as
can be concluded from the substantial percentage of those
with hypothyroidism who had negative TPOAbs in our
study. Mild thyroid failure attributable to autoimmunity
could well contribute to this skewed distribution. It is also
important to acknowledge that population-based refer-
ence intervals have limitations when used for the inter-
pretation of results of individual TSH values, because
changes in an individual may remain undetected because
of the high degree of intraindividual variance for TSH
(31, 32).
In conclusion, our survey is the largest European popu-
lation-based study to date to provide extensive data on
serum FT4, TSH (using a third-generation assay), and
TPOAbs (using a sensitive assay). We found that serum
TSH decreases gradually with age, whereas serum FT4
increases with age in individuals older than 60 years,
possibly because of development of thyroid autonomy
after longstanding borderline sufficient iodine intake in
the eastern part of The Netherlands. Excluding those at
risk for thyroid disease lowers the upper limit of the TSH
reference interval considerably.
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Ben Risbourg and Hanno Braak (Ortho-Clinical Diagnos-
tics, Beerse, Belgium) for supplying a substantial part of
the FT4 assay reagents. We thank Andrew Tan and Siem
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